Aurobindo-Lannett, In the Matter of
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
The FTC is requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.
At the Federal Trade Commission’s request, a federal court has temporarily halted a sprawling enterprise of deceptive subscription schemes—comprised of 15 corporations and eight individuals—from continuing to deceive consumers with hidden costs and recurring charges, while failing to provide simple mechanisms to cancel subscriptions.
The Federal Trade Commission, along with Alaska, Iowa, Nebraska and Texas, today filed a lawsuit against the World Professional Association for Transgender Health (WPATH), alleging the organization has provided the means for medical providers to make false and unsubstantiated claims to parents in order to sell pediatric medical transition services.